ONEPOINT Launches Next Generation Project Life Cycle Support with Planforge 22
28.2.2023 11:00:00 EET | Business Wire | Press release
ONEPOINT, a Gartner leader in adaptive project management and reporting, today launched its new Planforge platform — the successor to its hybrid PPM software ONEPOINT Projects. The first major release, Planforge 22, focuses on providing next-generation project life cycle support for agile and traditional projects and programs, including a new dynamic project closure process, modernized change requests, vastly enhanced standard reports, and support for RACI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005123/en/
Planforge 22 supports a new dynamic project closure, lessons learned, and more. (Graphic: Business Wire)
"Planforge is our next step in making hybrid PPM more accessible and powerful at the same time," said Gerald Aquila, founder and CEO of ONEPOINT. "By implementing best practices and lessons learned from hundreds of customer projects analyzed by leading PPM consultants, our software has distinctive built-in project management expertise that is unique in the market."
Dynamic Project Closure
Built around an always accessible project closure form, the new dynamic project closure process is the cornerstone of many practical enhancements to the new Planforge platform:
- 1–5-star ratings and comments for overall project success, each objective and KPI
- Post-project phase can be easily planned using to-dos
- Lessons learned can be added at any time
- Redesigned project closure PDF standard report is based on new capabilities
Lessons Learned
Besides playing an essential role in the new project closure process, lessons learned are real lightweight business objects that are fully reportable using Planforge's flexible report wizard.
"This is a major first step to preserving important project know-how and providing transparency and important learnings to all project stakeholders. Learning from past mistakes and applying successes to future projects is becoming a key success factor," stated Dieter Freismuth, CTO of ONEPOINT.
Modernized Change Requests
Another success factor is effective change request management. By completely redesigning the way change requests are entered and displayed in Planforge, ONEPOINT has managed to incorporate latest best practices while simplifying the user interface. ONEPOINT made change requests more dynamic by allowing project managers to delegate ownership and prioritize changes. Additionally, the Planforge platform now includes a built-in, customizable standard report for a change request.
RACI
Other enhancements include support for RACI, enabling project managers to improve their overview of team responsibilities for complex projects and programs.
Availability
Planforge is available for free for up to 4 users both as a cloud service and on-premises. ONEPOINT also provides different plans for extended connectivity, including a bidirectional integration to Atlassian's Jira. Sign up now at www.planforge.io.
About
ONEPOINT Projects empowers teams to make projects work. With its Planforge hybrid PPM software, ONEPOINT simplifies daily project work with a practical approach to project and portfolio management and enterprise agile planning. Recognized as a Gartner APMR leader, ONEPOINT builds on major standards such as IPMA, PMI, PRINCE2, and SAFe, enabling project-driven organizations to increase project and portfolio transparency, reduce time to market, and optimize resource utilization.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005123/en/
Contact information
ONEPOINT Projects GmbH
Kerstin Gaar
press@onepoint-projects.com
www.planforge.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom